Introduction
Cholecystokinin (CCK) is a sulfated neuropeptide hormone and neurotransmitter synthesized by cells in the mucosal epithelium of the small intestine and secreted in the duodenum. The C-terminal fragment CCK-8, inhibits gastric emptying as well as other physiological processes involved in satiety.
Results and Discussion
While the physiological effects of inhibiting gastric emptying, decreasing gastric acid secretion and satiety make CCK-8 an interesting peptide for the treatment of obesity, the anxiolytic effect which is normally attributed to the Cholecystokinin B receptor, complicate its use. In our research, we sought to synthesize a long acting peptide CCK agonist which was selective for the CCK-A receptor, had desired potency and sufficient solubility to be dosed using an implanted osmotic mini pump. To do this, we used much of the data which has been previously reported and attempted to systematically assemble it into a single peptide agonist with the desired pharmacokinetic profile.  Activity is restored to non-sulfated CCK-4 when Met31 is replaced with a Lys(Tac) residue [2]  Hexapeptide analogs retain potency when both Met28 and Met31 are replaced with norleucine [3]  N-methyl-Phenylalanine enhances metabolic stability [4]  N-terminal pGlu-Gln enhances metabolic stability [5] The literature modifications were systematically incorporated, resulting in peptide 34 (Table 1) which had the desired potency, selectivity, food intake reduction and a solubility > 150 mg/mL. While endogenous CCK-8 lacks the selectivity duration of action and solubility to be used as an effective tool compound in combination studies, the introduction of modifications to the peptide sequence gleaned from the literature enabled us to generate a suitable molecule. 
